Charles River Laboratories and Gazi University Launch Gene Therapy Collaboration

Reuters01-21
Charles River Laboratories and Gazi University Launch Gene Therapy Collaboration

Charles River Laboratories International Inc. has entered into a gene therapy contract development and manufacturing organization $(CDMO)$ collaboration with Gazi University Faculty of Medicine. The partnership aims to advance rare disease research at Gazi University by providing plasmid DNA for AAV production and in vitro efficacy studies. Through this collaboration, Charles River will supply off-the-shelf, research-grade AAV plasmids, produced with animal component-free methods, to support early-stage gene therapy programs. This initiative is expected to accelerate the development of transformative therapies for rare diseases, leveraging Charles River’s expertise in cell and gene therapy manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121488189) on January 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment